Ep. 75: Catherine Wood: Tesla Leads These Tech Stocks Surging Higher As Innovations Accelerate
Investing With IBD
00:00
Editas Medicine Is Battling Out for Patents for CRISPR Technology
Editas medicine, right, ticker symbol, EDIT. Why CRISPR over EDitas? Well, we own CRISPR therapeutics, editas, and Intellia. Those are the three companies with the foundational patents for CRISPR gene editing. This is for Cas9, which is a particular enzyme, and seems to be the one that is finding most success right now.
Transcript
Play full episode
